Preferentially expressed antigen in melanoma (PRAME)—a poor-prognosis tumor antigen—co-regulates multiple checkpoint molecules (PD-1/PD-L1/Gal-9) through epigenetic silencing effects (76). Here, LGALS9 is linked to melanoma.